0001778922-26-000033
SEC filingSpyGlass Pharma reported Q1 2026 net loss of $13.8 million with $251.0 million in cash funding operations through 2028, alongside positive Phase 1/2 BIM-IOL data and Phase 3 enrollment progress.
SpyGlass Pharma's Q1 2026 results reflect a pre-revenue biopharma in late-stage development, with net loss widening to $13.8 million from $8.8 million year-over-year due to increased investments in clinical programs. R&D expenses rose 41% to $8.5 million, attributed to hiring clinical personnel for ongoing Phase 3 trials of the BIM-IOL System, while G&A surged over 400% to $6.9 million from higher professional services and headcount post-IPO. The February 2026 IPO, raising $172.5 million in gross proceeds including the underwriters' option, bolstered the balance sheet, ending the quarter with $251.0 million in cash, equivalents, and short-term investments—sufficient to fund operations through 2028 without near-term dilution risk. CEO Patrick Mooney highlighted the company's focus on BIM-IOL, which integrates sustained bimatoprost delivery during cataract surgery to eliminate daily eye drops for glaucoma patients, and BIM-DRS for broader retreatment potential. Phase 1/2 topline data showed compelling efficacy at the 78-mcg dose: 34% mean IOP reduction, 98% drop-free, and visual acuity matching premium monofocal IOLs, with a safety profile akin to standard cataract procedures. Phase 3 trials SGP-005 and SGP-006 have initiated surgeries, targeting enrollment completion in 2027 to support NDA submission. Upcoming catalysts include four-year Phase 1/2 follow-up in Q4 2026 and BIM-DRS FIH trial in H2 2026, positioning SpyGlass for potential market expansion in glaucoma treatment.